News
Pharvaris N.V. ('Pharvaris,” Nasdaq: PHVS), a late-stage biopharmaceutical company developing novel, oral bradykinin B2 receptor antagonists to address unmet needs of those living with ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback